Docetaxel in Non Small Cell Lung Cancer (NSCLC)

PHASE2CompletedINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

October 31, 2001

Primary Completion Date

September 30, 2007

Conditions
Lung Neoplasms
Interventions
DRUG

Docetaxel + carboplatin + radiotherapy + docetaxel + gemcitabine

Docetaxel 20 mg/m²/week with carboplatin AUC 2/week and concomitant radiotherapy up to 60 Gy. Further on, 2 Docetaxel cycles and gemcitabine according to arm 2.

OTHER

Docetaxel + gemcitabine + carboplatin + radiotherapy

Docetaxel 40 mg/ m² days 1, 8, 21 and 28 with gemcitabine 1200 mg/ m² days 1, 8, 21 and 28 followed by concomitant treatment with docetaxel 20 mg/m²/week with carboplatin AUC 2/week and concomitant radiotherapy up to 60 Gy (2 Gy/day, 5 days per week and for 6 weeks).

Trial Locations (1)

Unknown

Sanofi-Aventis, Barcelona

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Sanofi

INDUSTRY